Kenvue Inc. (NYSE:KVUE) Shares Acquired by RBO & Co. LLC

RBO & Co. LLC lifted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 1.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,003,775 shares of the company's stock after purchasing an additional 12,356 shares during the period. Kenvue accounts for approximately 3.5% of RBO & Co. LLC's portfolio, making the stock its 9th biggest holding. RBO & Co. LLC owned 0.05% of Kenvue worth $21,431,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in KVUE. Grove Bank & Trust raised its position in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Kenvue in the 4th quarter valued at approximately $29,000. SRS Capital Advisors Inc. lifted its position in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after acquiring an additional 571 shares during the period. Fortitude Family Office LLC grew its holdings in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in shares of Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after purchasing an additional 1,441 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Price Performance

Shares of KVUE stock traded up $0.02 during trading hours on Friday, hitting $23.98. 14,097,083 shares of the company's stock were exchanged, compared to its average volume of 17,031,836. The stock's 50-day moving average is $23.09 and its 200-day moving average is $22.50. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The stock has a market cap of $46.01 billion, a price-to-earnings ratio of 45.25, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.42%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Evercore ISI started coverage on shares of Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 price target on the stock. UBS Group lowered their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Redburn Atlantic initiated coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target for the company. Piper Sandler upped their price objective on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Finally, Canaccord Genuity Group increased their target price on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.